Arizona officials have approved and funded a first-in-the-nation clinical trial investigating the potential of whole mushroom psilocybin to treat post-traumatic stress disorder (PTSD) in first responders and military veterans—with authorization from the federal Food and Drug Administration (FDA).
The state-funded study is being spearheaded by the Scottsdale Research Institute (SRI), with support from the research firm Alira Health. The initial trial will involve eight police officers, eight firefighters and eight military veterans diagnosed with PTSD who will receive the psychedelic in a medically supervised environment.
With backing from the Arizona Department of Health Services (ADHS), the historic research project is being made possible by the enactment of a spending bill Gov. Katie Hobbs (D) signed into law in 2023 that earmarked $5 million in grants for psilocybin studies.
“Scientific progress is essential to ensuring that our healthcare decisions are informed by rigorous research and sound data,” Nicole Nichols, executive director at SRI, said in a press release on Tuesday.
The FDA-controlled trial will involve 24 participants with PTSD who will take 30 milligrams of psilocybin from about 4.5 grams of whole psilocybin mushrooms, grown at SRI’s facility that operates under a Drug Enforcement Administration (DEA) Schedule I manufacturer license.
Arizona
Read full article on Marijuana Moment
